Tesileanu, C. Mircea S.
Vallentgoed, Wies R.
Sanson, Marc
Taal, Walter
Clement, Paul M.
Wick, Wolfgang
Brandes, Alba Ariela
Baurain, Jean Francais
Chinot, Olivier L.
Wheeler, Helen
Gill, Sanjeev
Griffin, Matthew
Rogers, Leland
Rudà, Roberta
Weller, Michael
McBain, Catherine
Reijneveld, Jaap
Enting, Roelien H.
Caparrotti, Francesca
Lesimple, Thierry
Clenton, Susan
Gijtenbeek, Anja
Lim, Elizabeth
de Vos, Filip
Mulholland, Paul J.
Taphoorn, Martin J. B.
de Heer, Iris
Hoogstrate, Youri
de Wit, Maurice
Boggiani, Lorenzo
Venneker, Sanne
Oosting, Jan
Bovée, Judith V. M. G.
Erridge, Sara
Vogelbaum, Michael A.
Nowak, Anna K.
Mason, Warren P.
Kros, Johan M.
Wesseling, Pieter
Aldape, Ken
Jenkins, Robert B.
Dubbink, Hendrikus J.
Baumert, Brigitta
Golfinopoulos, Vassilis
Gorlia, Thierry
van den Bent, Martin
French, Pim J. http://orcid.org/0000-0002-0668-9529
Funding for this research was provided by:
Brain Tumour Charity (GN-000577)
KWF Kankerbestrijding (10685)
Strijd van Salland
U.S. Department of Defense (CA170278)
Article History
Received: 30 December 2020
Revised: 5 February 2021
Accepted: 23 February 2021
First Online: 19 March 2021
Declarations
:
: MS reports research grants from Astra-Zeneca, travel grant from Abbvie, personal fees from Genenta, outside the submitted work, PM reports support to attend conferences from BMS and an award towards an investigator-initiated study from BMS. BB reports a MERCK grant for the EORTC22033 lGG study. MAV has indirect equity interest and royalty rights from Infuseon Therapeutics, Inc. He has received honoraria from Tocagen, Cellinta, and Celgene. None of these interests overlaps with the research presented in this manuscript. Wolfgang Wick receives trial funding from Apogenix, Boehringer Ingelheim, Pfizer and Roche to the institution. He serves on advisory boards for Agios, Bayer, MSD, Novartis, Roche with compensation paid to the institution. MJvdB reports grants from Dutch Cancer Foundation, grants from Brain Tumor Charity, grants from Strijd van Salland, grants from MSD formerly Schering Plough, during the conduct of the study; personal fees from Carthera, personal fees from Nerviano, personal fees from Bayer, personal fees from Celgene, personal fees from Agios, personal fees from Abbvie, personal fees from Karyopharm, personal fees from Boston Pharmaceuticals, personal fees from Genenta, outside the submitted work. AN received research funding from Astra Zeneca, and Douglas Pharmaceuticals, consultancies for Bayer, Roche, Boehringer Ingelheim, MSD, Douglas Pharmaceuticals, Pharmabcine, Atara biotherapeutics, Trizell and Seagen. MW has received research grants from Abbvie, Adastra, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure and Quercis, and honoraria for lectures or advisory board participation or consulting from Abbvie, Adastra, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck, Sharp & Dohme (MSD), Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen, Roche and Tocagen. FdV reports support from AbbVie, Bioclin Therapeutics, BMS, GSK, Novartis, Octimed Oncology and Vaximm, outside the submitted work. PC reports support from BMS, AbbVie, Merck Serono, MSD, Vifor Pharma, Daiichi Sankyo, Leo Pharma and Astra Zeneca, outside the submitted work. PJF reports grants from Dutch Cancer Foundation, the Brain Tumor Charity, the Strijd van Salland, de Westlandse ride and Hersentumorfonds, outside submitted work. Other authors report no conflict of interest.